Review of: Bonnie L. Walker, Injury Prevention for the Elderly- A Research Guide (Greenwood Press 1995)

Review of: Bonnie L. Walker, Injury Prevention for the Elderly- A Research Guide (Greenwood Press 1995). Acknowledgments, appendices, author index, bibliographical references, foreword, preface, subject index. LC 95-32989; ISSN 0743-7560 [328 pp. Cloth $75.00. 88 Post Road West, Westport, CT 06881.

Systematic Review and Meta-Analysis of Preterm Birth and Later Systolic Blood Pressure

Lower birth weight because of fetal growth restriction is associated with higher blood pressure later in life, but the extent to which preterm birth ( <37 completed weeks' gestation) or very low birth weight ( <1500 g) predicts higher blood pressure is less clear. We performed a systematic review of 27 observational studies that compared the resting or ambulatory systolic blood pressure or diagnosis of hypertension among children, adolescents, and adults born preterm or very low birth weight with those born at term. We performed a meta-analysis with the subset of 10 studies that reported the resting systolic blood pressure difference in millimeters of mercury with 95% CIs or SEs. We assessed methodologic quality with a modified Newcastle-Ottawa Scale. The 10 studies were composed of 1342 preterm or very low birth weight and 1738 term participants from 8 countries. The mean gestational age at birth of the preterm participants was 30.2 weeks (range: 28.8-34.1 weeks), birth weight was 1280 g (range: 1098-1958 g), and age at systolic blood pressure measurement was 17.8 years (range: 6.3-22.4 years). Former preterm or very low birth weight infants had higher systolic blood pressure than term infants (pooled estimate: 2.5 mm Hg [95% CI: 1.7-3.3 mm Hg]). For the 5 highest quality studies, the systolic blood pressure difference was slightly greater, at 3.8 mm Hg (95% CI: 2.6-5.0 mm Hg). We conclude that infants who are born preterm or very low birth weight have modestly higher systolic blood pressure later in life and may be at increased risk for developing hypertension and its sequela

Multimodal imaging analyses of hyperreflective dot-like lesions in acute syphilitic posterior placoid chorioretinopathy

Background: Retrospective review of one acute syphilitic posterior placoid chorioretinitis (ASPPC) case with serological evidence of syphilis who had ocular signs and symptoms not attributable to other diseases. Enface and spectral-domain optical coherence tomographySD-OCT were analyzed at the time of presentation and at 1-month visit following initiation of treatment. The study patient underwent standard treatment for neurosyphilis. Results: Ophthalmic examination and imaging studies were consistent with the diagnosis of ASPPC. The patient age was 33 year-old and the baseline visual acuity was 20/400 and 20/80 in the right and left eyes, respectively. At presentation, SD-OCT scans showed disruption and loss of the ellipsoid zone (EZ), small nodular elevations on retinal pigment epithelium (RPE) and punctate hyperreflectivity in the choroid. Enface OCT at the level of RPE and EZ demonstrated multiple hyperreflective dot-like lesions simmetrically distributed within the macular area. These dot-like lesions corresponded to the small nodular elevations on RPE and to disruption/loss of EZ observed with SD-OCT. One month after neurosyphilis therapy, the visual acuity improved and the outer retinal changes partially reversed in both eyes. Conclusions: We report the outer retinal findings and its correlation using both en-face and SD-OCT in a patient with ASPPC. En-face OCT imaging provides a more precise outer retinal layers analyses allowing a better understanding of the ASPPC pathophysiology.Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, BrazilFed Univ Sao Paulo UNIFESP, Rua Botucatu,821,Vila Clementino, BR-04023062 Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, BrazilFed Univ Sao Paulo UNIFESP, Rua Botucatu,821,Vila Clementino, BR-04023062 Sao Paulo, SP, BrazilWeb of Scienc

Poda de frutificação na produtividade do urucuzeiro.

bitstream/item/60223/1/CPATU-PA165.pd

Discrimination between patients with acquired toxoplasmosis and congenital toxoplasmosis on the basis of the immune response to parasite antigens

Many persons infected with Toxoplasma gondii develop ocular lesions, Immunologic parameters in the response to I gondii were evaluated in infected persons with and without ocular lesions and in noninfected controls. Subjects were divided into groups on the basis of presence of serum antibodies to I: gondii, presence of ocular lesions, and clinical history. Production of interleukin-2 and interferon-gamma by peripheral blood mononuclear cells from patients with probable congenital toxoplasmosis was decreased, compared with that in persons with presumed acquired infection. Cell proliferation and delayed-type skin reaction induced by soluble toxoplasma tachyzoite antigen followed the same pattern. Asymptomatic persons showed high levels of interleukin-12 and interferon-gamma, whereas persons with ocular lesions had high interleukin-1 and tumor necrosis factor-alpha responses toward soluble toxoplasma tachyzoite antigen. These data suggest that patients with ocular disease due to congenital infection show tolerance toward the parasite. Furthermore, susceptibility to ocular lesions after acquired toxoplasmosis is associated with high levels of interleukin-1 and tumor necrosis factor-alpha, whereas resistance is associated with high levels of interleukin-12 and interferon-gamma.Univ São Paulo, ICB, Dept Immunol, BR-05509890 São Paulo, BrazilUniv São Paulo, Inst Heart, Lab Transplant Immunol, São Paulo, BrazilUniv São Paulo, Fac Med, Dept Ophthalmol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Ophthalmol, São Paulo, BrazilUniv São Paulo, Sch Med, Div Clin Immunol & Allergy, Lab Med Invest, São Paulo, BrazilFundacao EJ Zerbini, São Paulo, BrazilUniv Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, BrazilFundacao Osvaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, BrazilNEI, Immunol Lab, NIH, Bethesda, MD 20892 USAUniversidade Federal de São Paulo, Dept Ophthalmol, São Paulo, BrazilWeb of Scienc

Galactic Kinematics Towards the South Galactic Pole. First Results from the Yale-San Juan Southern Proper-Motion Program

The predictions from a Galactic Structure and Kinematic model code are compared to the color counts and absolute proper-motions derived from the Southern Proper-Motion survey covering more than 700 $\deg^2$ toward the South Galactic Pole in the range $9 < B_{\rm J} \le 19$. The theoretical assumptions and associated computational procedures, the geometry for the kinematic model, and the adopted parameters are presented in detail and compared to other Galactic Kinematic models of its kind. The data to which the model is compared consists of more than 30,000 randomly selected stars, and it is best fit by models with a solar peculiar motion of +5 km s$^{-1}$ in the V-component (pointing in the direction of Galactic rotation), a large LSR speed of 270 km s$^{-1}$, and a (disk) velocity ellipsoid that always points towards the Galactic center. The absolute proper-motions in the U-component indicate a solar peculiar motion of $11.0 \pm 1.5$ km s$^{-1}$, with no need for a local expansion or contraction term. The fainter absolute motions show an indication that the thick-disk must exhibit a rather steep velocity gradient of about -36 km s$^{-1}$ kpc$^{-1}$ with respect to the LSR. We are not able to set constraints on the overall rotation for the halo, nor on the thick-disk or halo velocity dispersions. Some substructure in the U & V proper-motions could be present in the brighter bins $10 < B_{\rm J} < 13$, and it might be indicative of (disk) moving groups.Comment: 24 double-column pages, 12 tables, AAS Latex macros v4.0, 19 B&W figures, 1 color figure. Accepted for publication on The Astronomical Journa

Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator

Zuranolone (SAGE-217) is a novel, synthetic, clinical stage neuroactive steroid GABAA receptor positive allosteric modulator designed with the pharmacokinetic properties to support oral daily dosing. In vitro, zuranolone enhanced GABAA receptor current at nine unique human recombinant receptor subtypes, including representative receptors for both synaptic (γ subunit-containing) and extrasynaptic (δ subunit-containing) configurations. At a representative synaptic subunit configuration, α1β2γ2, zuranolone potentiated GABA currents synergistically with the benzodiazepine diazepam, consistent with the non-competitive activity and distinct binding sites of the two classes of compounds at synaptic receptors. In a brain slice preparation, zuranolone produced a sustained increase in GABA currents consistent with metabotropic trafficking of GABAA receptors to the cell surface. In vivo, zuranolone exhibited potent activity, indicating its ability to modulate GABAA receptors in the central nervous system after oral dosing by protecting against chemo-convulsant seizures in a mouse model and enhancing electroencephalogram β-frequency power in rats. Together, these data establish zuranolone as a potent and efficacious neuroactive steroid GABAA receptor positive allosteric modulator with drug-like properties and CNS exposure in preclinical models. Recent clinical data support the therapeutic promise of neuroactive steroid GABAA receptor positive modulators for treating mood disorders; brexanolone is the first therapeutic approved specifically for the treatment of postpartum depression. Zuranolone is currently under clinical investigation for the treatment of major depressive episodes in major depressive disorder, postpartum depression, and bipolar depression